Study identifier:BY217/M2-012
ClinicalTrials.gov identifier:NCT00073177
EudraCT identifier:N/A
CTIS identifier:N/A
A 24 Week, Double-Blind, Randomized, Placebo-Controlled Clinical Trial to evaluate the Efficacy and Safety of Oral Roflumilast (250 mcg or 500 mcg) Daily in Patients with Asthma
asthma
Phase 3
No
Roflumilast
All
819
Interventional
18 Years - 70 Years
Allocation: Randomized
Endpoint Classification: None
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verified 01 Sept 2016 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|